Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Freeman

Showing results (801-810 of 920) with videos related to

Pageof 92
Sort By:
Kidney International|September 17, 2015
Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemiaDavid A Bushinsky, Gordon H Williams, Bertram Pitt, et al.
Psychosomatic Medicine|February 4, 2015
Placebo improvement in pharmacologic treatment of menopausal hot flashes: time course, duration, and predictorsEllen W Freeman, Kristine E Ensrud, Joseph C Larson, et al.
Cancer Research|October 16, 2003
Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferationKevin W Freeman, Rama D Gangula, Bryan E Welm, et al.
JAMA|July 15, 2015
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical TrialGeorge L Bakris, Bertram Pitt, Matthew R Weir, et al.
Journal of Cellular Biochemistry|August 27, 2015
Cross-Talk Between Human Tenocytes and Bone Marrow Stromal Cells Potentiates Extracellular Matrix Remodeling In VitroEmmanuel C Ekwueme, Jay V Shah, Mahir Mohiuddin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 24, 2002
Cellular activation, phagocytosis, and bactericidal activity against group B streptococcus involve parallel myeloid differentiation factor 88-dependent and independent signaling pathwaysPhilipp Henneke, Osamu Takeuchi, Richard Malley, et al.
The New England Journal of Medicine|November 7, 2022
Phase 2 Trial of Baxdrostat for Treatment-Resistant HypertensionMason W Freeman, Yuan-Di Halvorsen, William Marshall, et al.
The Journal of Clinical Endocrinology and Metabolism|July 12, 2014
Effects of escitalopram on markers of bone turnover: a randomized clinical trialSusan J Diem, Hadine Joffe, Joseph C Larson, et al.
Stroke|April 11, 2013
Negative diffusion-weighted imaging after intravenous tissue-type plasminogen activator is rare and unlikely to indicate averted infarctionJason W Freeman, Marie Luby, José G Merino, et al.
Translational Oncology|May 11, 2021
XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkBBasia Galinski, Marcus Luxemburg, Yosef Landesman, et al.
Pageof 92

Showing results (801-810 of 920) with videos related to

Sort By:
Pageof 92
Kidney International|September 17, 2015
Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemiaDavid A Bushinsky, Gordon H Williams, Bertram Pitt, et al.
Psychosomatic Medicine|February 4, 2015
Placebo improvement in pharmacologic treatment of menopausal hot flashes: time course, duration, and predictorsEllen W Freeman, Kristine E Ensrud, Joseph C Larson, et al.
Cancer Research|October 16, 2003
Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferationKevin W Freeman, Rama D Gangula, Bryan E Welm, et al.
JAMA|July 15, 2015
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical TrialGeorge L Bakris, Bertram Pitt, Matthew R Weir, et al.
Journal of Cellular Biochemistry|August 27, 2015
Cross-Talk Between Human Tenocytes and Bone Marrow Stromal Cells Potentiates Extracellular Matrix Remodeling In VitroEmmanuel C Ekwueme, Jay V Shah, Mahir Mohiuddin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 24, 2002
Cellular activation, phagocytosis, and bactericidal activity against group B streptococcus involve parallel myeloid differentiation factor 88-dependent and independent signaling pathwaysPhilipp Henneke, Osamu Takeuchi, Richard Malley, et al.
The New England Journal of Medicine|November 7, 2022
Phase 2 Trial of Baxdrostat for Treatment-Resistant HypertensionMason W Freeman, Yuan-Di Halvorsen, William Marshall, et al.
The Journal of Clinical Endocrinology and Metabolism|July 12, 2014
Effects of escitalopram on markers of bone turnover: a randomized clinical trialSusan J Diem, Hadine Joffe, Joseph C Larson, et al.
Stroke|April 11, 2013
Negative diffusion-weighted imaging after intravenous tissue-type plasminogen activator is rare and unlikely to indicate averted infarctionJason W Freeman, Marie Luby, José G Merino, et al.
Translational Oncology|May 11, 2021
XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkBBasia Galinski, Marcus Luxemburg, Yosef Landesman, et al.
Pageof 92